Aegle Therapeutics is conducting a Phase 1/2A, non-randomized, multi-center, ascending dose, study to assess the effectiveness and safety of AGLE-102 on lesions in subjects with Recessive Dystrophic Epidermolysis Bullosa (RDEB).
AGLE-102 is a topical agent composed of native extracellular vesicles (EVs) derived from donor mesenchymal stem cells (MSCs) - special cells in your body that can act like repair crews and have the power to help fix and regenerate different tissues.
The aim of the study is to assess the safety and efficacy of AGLE-102 in the treatment of lesions in subjects with RDEB.
Compensation to support travel to the clinical trial sites will be offered.
- Confirmed diagnosis of DEB as determined by electron microscopy, immunomapping, or genetic testing.
- Have one or more active wounds (unroofed EB erosions) each between 10 and 50 cm2 on arms, legs, or trunk.
Visit clinicaltrials.gov for a full list of inclusion and exclusion criteria.
If you have questions regarding the RDEB AGLE-102 Clinical Trial, or if you are interested in participating, please contact the study coordinator for each trial site:
All three sites are open for adult enrollment. Children's Hospital of Philadelphia (CHOP) also has IRB approval to treat patients 6 months of age and older. Approval to treat pediatric patients at the other two sites is anticipated soon. Travel compensation will be provided.
- University of Southern California (Los Angeles, CA):
- Study Coordinator: Kathleen Miao
- Email: klmiao@usc.edu
- Phone: 626-315-6856
- Study Coordinator: Kathleen Miao
- Phoenix Children's Hospital (Phoenix, AZ):
- Study Coordinator: Kellie Badger, BS, RN
- Email: kbadger@phoenixchildrens.com
- Phone: 602-933-2053
- Study Coordinator: Kellie Badger, BS, RN
- Children's Hospital of Philadelphia (Philadelphia, PA):
- Study Coordinator: Griffin Stockton-Hogrogian, MSEd
- Email: stocktonhg@chop.edu
- Study Coordinator: Griffin Stockton-Hogrogian, MSEd
See the AGLE-102 informational brochure
